Andy Richards receives BIA Lifetime Achievement Award
News Feb 13, 2013
He said: "It is truly gratifying to be honoured by the BIA in this way, and I would like to thank all of those who have worked with me. The UK life-science ecosystem is a tremendous community with the profound capacity to do real good. It punches well above its weight in global impact and has many more successes than are recognised and reported. As we enter the age of biology and personalised medicine it is a great place to be with great people."
As well as sitting on the BBSRC Council and BBSRC Audit Board, Dr Richards is a founder, active investor and director of more than 20 innovative healthcare and life-science companies over the last 12 years.
Tim Edwards, BIA Chairman, said: "Andy Richards is an enthusiast for and champion of UK bioscience. He has established numerous companies that are getting new medicines from an idea to approved products that help patients. He is a true leader in our sector who has continued to put his own money where his mouth is. Finally, and quite possibly most importantly, Andy spends time inspiring school and university students to be entrepreneurial and to consider following a career in an innovative sector, such as life sciences."
New Automated Screening Method for Identifying Drug CandidatesNews
Scientists at DESY have developed a new method that enables automated and fast screening of promising drug candidates.READ MORE
Metabolomic Profiling Identifies Taurine as New MS TherapeuticNews
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. The discovery also highlights the potential for a technique called “metabolomic profiling,” which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.READ MORE
Atomic Structure of 'Cold' Receptor Uncovered Aiding Therapeutic TargetingNews
A team of researchers have made the first determination of the atomic structure of Transient Receptor Potential Melastatin 8. This finding should boost ongoing efforts by scientists to target TRPM8 therapeutically.READ MORE